Abstract:Pediatric obesity is a chronic and growing problem for which new ideas about the biologic basis of obesity offer hope for effective solutions. Prevalence of pediatric and adult obesity is increasing despite a bewildering array of treatment programs and severe psychosocial and economic costs. The definition of obesity as an increase in fat mass, not just an increase in body weight, has profound influence on the understanding and treatment of obesity. In principle, body weight is determined by a balance between energy expenditure and energy intake, but this observation does not by itself explain obesity. There is surprisingly little evidence that the obese overeat and only some evidence that the obese are more sedentary. Understanding of the biologic basis of obesity has grown rapidly in the last few years, especially with the identification of a novel endocrine pathway involving the adipose tissue secreted hormone leptin and the leptin receptor that is expressed in the hypothalamus. Plasma leptin levels are strongly correlated with body fat mass and are regulated by feeding and fasting, insulin, glucocorticoids, and other factors, consistent with the hypothesis that leptin is involved in body weight regulation and may even be a satiety factor (Fig. 2, Table 1). Leptin injections have been shown to reduce body weight of primates, although human clinical trials will not be reported until summer 1997. So many peptides influencing feeding have been described that one or more may have therapeutic potential (Fig. 2, Table 1). Although the complexity of pathways regulating body weight homeostasis slowed the pace of understanding underlying mechanisms, these complexities now offer many possibilities for novel therapeutic interventions (Fig. 2). Obesity is a major risk factor for insulin resistance and diabetes, hypertension, cancer, gallbladder disease, and atherosclerosis. In particular, adults who were obese as children have increased mortality independent of adult weight. Thus, prevention programs for children and adolescents will have long-term benefits. Treatment programs focus on modification of energy intake and expenditure through decreased calorie intake and exercise programs. Behavior-modification programs have been developed to increase effectiveness of these intake and exercise programs. These programs can produce short-term weight loss. Long-term losses are more modest but achieved more successfully in children than in adults. Several drug therapies for obesity treatment recently have been approved for adults that produce sustained 5% to 10% weight losses but experience with their use in children is limited. Identification of the biochemical pathways causing obesity by genetic approaches could provide the theoretic foundation for novel, safe, and effective obesity treatments. The cloning of leptin in 1994 has already led to testing the efficacy of leptin in clinical trials that are now underway. Although novel treatments of obesity are being developed as a result of the new biology of obesity, prevention of obesity remains an important goal.

Approach to the Treatment of Children and Adolescents with Obesity

Pediatric Obesity: Complications and Current Day Management

Childhood and Adolescent Obesity: A Review

Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease

Converging Pathways between Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Diabetes in Children

Steatotic Liver Disease in Pediatric Obesity and Increased Risk for Youth-Onset Type 2 Diabetes

Current and future state of pharmacological management of pediatric obesity

Treating Children and Adolescents With Obesity: Characteristics of Success

Pediatric obesity and insulin resistance: chronic disease risk and implications for treatment and prevention beyond body weight modification

Metabolic Consequences of Pediatric Obesity: A Review of Pathophysiology, Screening, and Treatment

Obesity management in the pediatric patient

Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity

Risk Factors, Clinical Consequences, Prevention, and Treatment of Childhood Obesity

The combined pioglitazone and topiramate therapy for management of pediatric patients with severe MASLD

Nutritional Approaches in Children with Overweight or Obesity and Hepatic Steatosis

Pediatric obesity. An overview of etiology and treatment

Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children

Bariatric surgery in the treatment of adolescent obesity: current perspectives in the United States

Pediatric obesity: Causes, symptoms, prevention and treatment

Beyond Obesity and Overweight: the Clinical Assessment and Treatment of Excess Body Fat In Children

An evidence‐based resource for the management of comorbidities associated with childhood overweight and obesity